Maxim Group upgraded Cellectar Biosciences (NasdaqCM: CLRB) from Hold to Buy on March 10, 2026, with a price forecast implying a 1,456.49% upside. The upgrade is a strong positive analyst signal that could spur near-term investor interest and share buying, but it is analyst-driven rather than company- or regulator-driven and should be validated against clinical or fundamental catalysts.
Maxim Group upgraded Cellectar Biosciences (NasdaqCM: CLRB) from Hold to Buy on March 10, 2026, with a price forecast implying a 1,456.49% upside. The upgrade is a strong positive analyst signal that could spur near-term investor interest and share buying, but it is analyst-driven rather than company- or regulator-driven and should be validated against clinical or fundamental catalysts.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
